Amgen Cleared Again On Kanjinti As Trial Looms
Denial Of Preliminary Injunction Upheld On Appeal
With an infringement trial set to begin next month, Amgen can continue to sell its Kanjinti trastuzumab biosimilar in the US after a Court of Appeals shot down originator Genentech's latest bid to block sales of the rival to its Herceptin blockbuster.
You may also be interested in...
Amgen has filed to settle on undisclosed terms patent-infringement litigation involving both its Kanjinti and Mvasi biosimilars, having previously seen originator Genentech fail multiple times to block commercial sales of the products that were launched ‘at risk’.
Amgen has launched its Kanjinti biosimilar version of trastuzumab in the US after a court refused Genentech’s request for an injunction. At the same time, Amgen has also introduced its Mvasi bevacizumab biosimilar. The launches represent Amgen’s first biosimilar introductions in the US.
With its own interests in the branded eye-disease space, Regeneron has commented on ranibizumab biosimilar sponsor Biogen’s fortunes during a recent conference.